Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Taisuke Araki, Shintaro Kanda, Hidehito Horinouchi & Yuichiro Ohe. (2023)
Current treatment strategies for
EGFR
-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
. Japanese Journal of Clinical Oncology 53:7, pages 547-561.
Crossref
Crossref
Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism
1
33
.
Munindra Ruwali, Keshav Moharir, Sanjiv Singh, Punita Aggarwal & Manash K. Paul. 2021. Pharmacogenetics. Pharmacogenetics.
Zhengyu Yang, Ya Chen, Yanan Wang, Shuyuan Wang, Minjuan Hu, Bo Zhang & Baohui Han. (2021) Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations. Frontiers in Oncology 11.
Crossref
Crossref
Yamei Huang, Dengchao Xie, Shuangquan Gou, Brandon S. B. Canup, Guizheng Zhang, Fangyin Dai, Changming Li & Bo Xiao. (2021) Quadruple-responsive nanoparticle-mediated targeted combination chemotherapy for metastatic breast cancer. Nanoscale 13:11, pages 5765-5779.
Crossref
Crossref
Gulam Mohmad Rather, Michael Anyanwu, Tamara Minko, Olga Garbuzenko, Zoltan Szekely & Joseph R. Bertino. (2021) Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin. Cancers 13:5, pages 972.
Crossref
Crossref
Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, Nandkumar Kadam, Nilesh Daware, Atanu Bhattacharjee, Srushti Shah, Akanksha Yadav, Vaishakhi Trivedi, Vichitra Behel, Amit Dutt, Shripad Dinanath Banavali & Kumar Prabhash. (2020)
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
EGFR
-Mutated Lung Cancer
. Journal of Clinical Oncology 38:2, pages 124-136.
Crossref
Crossref
Jordan Mandel, Huabo Wang, Daniel P. Normolle, Wei Chen, Qi Yan, Peter C. Lucas, Panayiotis V. Benos & Edward V. Prochownik. (2019) Expression patterns of small numbers of transcripts from functionally-related pathways predict survival in multiple cancers. BMC Cancer 19:1.
Crossref
Crossref
Lamia H.T. Amin, Taghreed Z. Shawer, Abeer M. El-Naggar & Hend M.A. El-Sehrawi. (2019) Design, synthesis, anticancer evaluation and docking studies of new pyrimidine derivatives as potent thymidylate synthase inhibitors. Bioorganic Chemistry 91, pages 103159.
Crossref
Crossref
Sherise D. Ferguson, Shouhao Zhou, Joanne Xiu, Yuuri Hashimoto, Nader Sanai, Lyndon Kim, Santosh Kesari, John de Groot, David Spetzler & Amy B. Heimberger. (2017) Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget 9:8, pages 7822-7831.
Crossref
Crossref
Elisa Giovannetti, Paolo A. Zucali, Christian Rolfo, Yehuda G. Assaraf & Godefridus J. Peters. (2016) Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. Journal of Clinical Oncology 34:5, pages 511-512.
Crossref
Crossref
Abolfazl Avan, Ravi Narayan, Elisa Giovannetti & Godefridus J Peters. (2016) Role of Akt signaling in resistance to DNA-targeted therapy. World Journal of Clinical Oncology 7:5, pages 352.
Crossref
Crossref
Saman Maleki Vareki, Di Chen, Christine Di Cresce, Peter J. Ferguson, Rene Figueredo, Macarena Pampillo, Mateusz Rytelewski, Mark Vincent, Weiping Min, Xiufen Zheng & James Koropatnick. (2015) IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells. PLOS ONE 10:11, pages e0143435.
Crossref
Crossref
Kaamar Azijli, Ingrid A. M. van Roosmalen, Jorn Smit, Saravanan Pillai, Masakazu Fukushima, Steven de Jong, Godefridus J. Peters, Irene V. Bijnsdorp & Frank A. E. Kruyt. (2014) The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology 73:6, pages 1273-1283.
Crossref
Crossref
Vidya P. Kumar, Kathleen M. Frey, Yiqiang Wang, Hitesh K. Jain, Aleem Gangjee & Karen S. Anderson. (2013) Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors. Bioorganic & Medicinal Chemistry Letters 23:19, pages 5426-5428.
Crossref
Crossref
Virginie Frings, Astrid A. M. van der Veldt, Ronald Boellaard, Gerarda J. M. Herder, Elisa Giovannetti, Richard Honeywell, Godefridus J. Peters, Erik Thunnissen, Otto S. Hoekstra & Egbert F. Smit. (2013) Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3?-Deoxy-3?-[18F]fluorothymidine Positron Emission Tomography. PLoS ONE 8:5, pages e63705.
Crossref
Crossref
Adi F Gazdar. (2012) The evolving role of the pathologist in the management of lung cancer. Lung Cancer Management 1:4, pages 273-281.
Crossref
Crossref
Vassiliki Kotoula, Dimitrios Krikelis, Vasilios Karavasilis, Triantafillia Koletsa, Anastasia G Eleftheraki, Despina Televantou, Christos Christodoulou, Stefanos Dimoudis, Ippokratis Korantzis, Dimitrios Pectasides, Konstantinos N Syrigos, Paris A Kosmidis & George Fountzilas. (2012) Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer 12:1.
Crossref
Crossref
Marcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, Andrea Camerini, Francesco Di Costanzo, Fausto Barbieri, Jacobus A. Burgers, Andrew Vincent, Godefridus J. Peters, Egbert F. Smit & Andrea Ardizzoni. (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed?carboplatin. Lung Cancer 78:1, pages 92-99.
Crossref
Crossref
Elena Galvani, Godefridus J Peters & Elisa Giovannetti. (2012) EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncology 8:8, pages 1015-1029.
Crossref
Crossref
Nitzan Gonen & Yehuda G. Assaraf. (2012) Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resistance Updates 15:4, pages 183-210.
Crossref
Crossref
Elisa Giovannetti, Francesca Toffalorio, Tommaso De Pas & Godefridus J Peters. (2012) Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 13:9, pages 1073-1086.
Crossref
Crossref
Peter M. Wilson, Melissa J. LaBonte, Heinz-Josef Lenz, Philip C. Mack & Robert D. Ladner. (2012) Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 11:3, pages 616-628.
Crossref
Crossref
Susanna Bazzani, Andreas Hoppe & Hermann-Georg Holzh?tter. (2012) Network-based assessment of the selectivity of metabolic drug targets in Plasmodium falciparum with respect to human liver metabolism. BMC Systems Biology 6:1, pages 118.
Crossref
Crossref
Amélie Lansiaux. (2011) Les antimétabolites. Bulletin du Cancer 98:11, pages 1263-1274.
Crossref
Crossref